Jump to content

Draft:Roy Kishony

From Wikipedia, the free encyclopedia


Roy Kishony is a biophysicist and systems biologist renowned for his pioneering research on antibiotic resistance, microbial evolution, and computational biology. He currently serves as the Marilyn and Henry Taub Professor of Life Sciences at the Technion – Israel Institute of Technology, holding joint appointments in the Faculty of Biology (major), Faculty of Biomedicine, and the Faculty of Computer Science. Dr. Kishony is also a Visiting Scientist at the Broad Institute Center for Integrated Solutions for Infectious Diseases[1].

Early Life and Education

[edit]

Born in Israel, Kishony completed his B.A. in Physics and Mathematics at the Hebrew University of Jerusalem in 1992. He earned his Ph.D. in Physics from Tel Aviv University in 1999. Transitioning into biology, he conducted postdoctoral research at Princeton University and The Rockefeller University with Stanislas Leibler, focusing on microbial systems and evolutionary dynamics. [2]

Academic Career

[edit]

In 2003, Kishony established his independent laboratory at Harvard University, first as a Bauer Fellow[3] and later in the newly formed Department of Systems Biology at Harvard Medical School, where he was promoted to full professor in 2011.[4] In 2014, he returned to Israel to join the Technion, where he also served as the director of the Lorry I. Lokey Interdisciplinary Center for Life Sciences and Engineering.

Research Contributions

[edit]

Kishony's research integrates experimental biology, mathematical modeling, and ML/AI big-data analytics to study microbial evolution, particularly antibiotic resistance. His lab has made significant discoveries, including:

  • Discovering that drug combinations can suppress or even reverse antibiotic resistance, and explaining the principles of selection inversion.[5][6][7]
  • Developing the MEGA-plate experiment, a large-scale visualization of bacterial evolution and natural selection under antibiotic stress, which has garnered over 30 million views online.[8]
  • Creating AI-based algorithms for personalized antibiotic prescriptions, aiding clinicians in selecting effective treatments for infections like urinary tract infections.[9][10]
  • Quantified the community level impact of COVID-19 vaccination.[11][12][13]
  • Created the first "AI scientist" capable of performing autonomous research from data alone to complete human-verifiable research papers. See Data-to-Paper[14][15].

Selected Publications

[edit]

Kishony has authored many peer-reviewed articles.[16]

Honors and Recognition

[edit]

Kishony's work has earned him numerous accolades, including:

  • 2022       Rappaport Prize for an Established Researcher
  • 2021       Landau Award in Bioinformatics
  • 2018       Member, European Academy of Microbiology (EAM)
  • 2017       Election, European Molecular Biology Organization (EMBO).[17]
  • 2017       Member, 8400 – The Health Network
  • 2016       Member, Israel Young Academy
  • 2016       Michael Bruno Memorial Award
  • 2013       Sanofi – Institut Pasteur Award
  • 2009       Outstanding Achievement in Biomedical Science Award, Genzyme[18]
[edit]
  • The Kishony Lab at Technion.[19]
  • Google Scholar page for Roy Kishony.[20]
  • Video of the MEGA plate evolution experiment.[1]

References

[edit]
  1. ^ "People". CISID. Retrieved 2025-05-19.
  2. ^ "about". www.rappaport-prize.org.il. Retrieved 2025-05-19.
  3. ^ "Roy Kishony". iias.huji.ac.il. Retrieved 2025-05-19.
  4. ^ Dougherty, Elizabeth (12/4/2009). "The Biology of Failure: Why Some Drug Combinations Backfire". Harvard Medical School News & Research. {{cite web}}: Check date values in: |date= (help)
  5. ^ Chait, Remy; Craney, Allison; Kishony, Roy (April 2007). "Antibiotic interactions that select against resistance". Nature. 446 (7136): 668–671. Bibcode:2007Natur.446..668C. doi:10.1038/nature05685. ISSN 1476-4687. PMID 17410176.
  6. ^ Lázár, Viktória; Snitser, Olga; Barkan, Daniel; Kishony, Roy (October 2022). "Antibiotic combinations reduce Staphylococcus aureus clearance". Nature. 610 (7932): 540–546. Bibcode:2022Natur.610..540L. doi:10.1038/s41586-022-05260-5. ISSN 1476-4687. PMC 9533972. PMID 36198788.
  7. ^ "Drugs That Invert Selection for Resistance". gcgh.grandchallenges.org. Retrieved 2025-05-19.
  8. ^ Baym, Michael; Lieberman, Tami D.; Kelsic, Eric D.; Chait, Remy; Gross, Rotem; Yelin, Idan; Kishony, Roy (2016-09-09). "Spatiotemporal microbial evolution on antibiotic landscapes". Science. 353 (6304): 1147–1151. Bibcode:2016Sci...353.1147B. doi:10.1126/science.aag0822. PMC 5534434. PMID 27609891.
  9. ^ Yelin, Idan; Snitser, Olga; Novich, Gal; Katz, Rachel; Tal, Ofir; Parizade, Miriam; Chodick, Gabriel; Koren, Gideon; Shalev, Varda; Kishony, Roy (July 2019). "Personal clinical history predicts antibiotic resistance of urinary tract infections". Nature Medicine. 25 (7): 1143–1152. doi:10.1038/s41591-019-0503-6. ISSN 1546-170X. PMC 6962525. PMID 31273328.
  10. ^ Stracy, Mathew; Snitser, Olga; Yelin, Idan; Amer, Yara; Parizade, Miriam; Katz, Rachel; Rimler, Galit; Wolf, Tamar; Herzel, Esma; Koren, Gideon; Kuint, Jacob; Foxman, Betsy; Chodick, Gabriel; Shalev, Varda; Kishony, Roy (2022-02-25). "Minimizing treatment-induced emergence of antibiotic resistance in bacterial infections". Science. 375 (6583): 889–894. Bibcode:2022Sci...375..889S. doi:10.1126/science.abg9868. PMC 7612469. PMID 35201862.
  11. ^ Milman, Oren; Yelin, Idan; Aharony, Noga; Katz, Rachel; Herzel, Esma; Ben-Tov, Amir; Kuint, Jacob; Gazit, Sivan; Chodick, Gabriel; Patalon, Tal; Kishony, Roy (August 2021). "Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals". Nature Medicine. 27 (8): 1367–1369. doi:10.1038/s41591-021-01407-5. ISSN 1546-170X. PMID 34113015.
  12. ^ Levine-Tiefenbrun, Matan; Yelin, Idan; Katz, Rachel; Herzel, Esma; Golan, Ziv; Schreiber, Licita; Wolf, Tamar; Nadler, Varda; Ben-Tov, Amir; Kuint, Jacob; Gazit, Sivan; Patalon, Tal; Chodick, Gabriel; Kishony, Roy (May 2021). "Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine". Nature Medicine. 27 (5): 790–792. doi:10.1038/s41591-021-01316-7. ISSN 1546-170X. PMID 33782619.
  13. ^ Levine-Tiefenbrun, Matan; Yelin, Idan; Alapi, Hillel; Katz, Rachel; Herzel, Esma; Kuint, Jacob; Chodick, Gabriel; Gazit, Sivan; Patalon, Tal; Kishony, Roy (December 2021). "Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2". Nature Medicine. 27 (12): 2108–2110. doi:10.1038/s41591-021-01575-4. ISSN 1546-170X. PMID 34728830.
  14. ^ Ifargan, Tal; Hafner, Lukas; Kern, Maor; Alcalay, Ori; Kishony, Roy (January 2025). "Autonomous LLM-Driven Research — from Data to Human-Verifiable Research Papers". NEJM AI. 2 (1). arXiv:2404.17605. doi:10.1056/AIoa2400555. ISSN 2836-9386.
  15. ^ Technion-Kishony-lab/data-to-paper, Technion-Kishony-lab, 2025-05-19, retrieved 2025-05-19
  16. ^ "Kishony R[Author] - Search Results - PubMed". PubMed. Retrieved 2025-05-19.
  17. ^ "Find people in the EMBO Communities". people.embo.org. Retrieved 2025-05-19.
  18. ^ "Kishony - פקולטה לביולוגיה Biology Faculty". 2021-08-19. Retrieved 2025-05-19.
  19. ^ "Home". Kishony lab. Retrieved 2025-05-19.
  20. ^ "Roy Kishony". scholar.google.co.il. Retrieved 2025-05-19.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:Roy_Kishony&oldid=1291212581"